Compile Data Set for Download or QSAR
Report error Found 113 Enz. Inhib. hit(s) with Target = 'Nuclear receptor ROR-gamma [258-518,Y502F]'
TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221253(US9303015, 27c | US9303015, 27b | US9303015, 27a)
Affinity DataIC50: 10nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231231(US9346782, 11b | US9346782, 11c | US9346782, 11a)
Affinity DataIC50: 15nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221234(US9303015, 8)
Affinity DataIC50: 16nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221257(US9303015, 31c | US9303015, 31b | US9303015, 31a)
Affinity DataIC50: 18nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221231(US9303015, 5c | US9303015, 5b | US9303015, 5a)
Affinity DataIC50: 28nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221256(US9303015, 30c | US9303015, 30b | US9303015, 30a)
Affinity DataIC50: 31nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221231(US9303015, 5c | US9303015, 5b | US9303015, 5a)
Affinity DataIC50: 39nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231232(US9346782, 12b | US9346782, 12c | US9346782, 12a)
Affinity DataIC50: 41nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231233(US9346782, 13c | US9346782, 13b | US9346782, 13a)
Affinity DataIC50: 46nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231233(US9346782, 13c | US9346782, 13b | US9346782, 13a)
Affinity DataIC50: 52nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221256(US9303015, 30c | US9303015, 30b | US9303015, 30a)
Affinity DataIC50: 58nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221235(US9303015, 9c | US9303015, 9b | US9303015, 9a)
Affinity DataIC50: 66nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221258(US9303015, 32c | US9303015, 32b | US9303015, 32a)
Affinity DataIC50: 66nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231234(US9346782, 14b | US9346782, 14c | US9346782, 14a)
Affinity DataIC50: 66nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221233(US9303015, 7)
Affinity DataIC50: 72nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221258(US9303015, 32c | US9303015, 32b | US9303015, 32a)
Affinity DataIC50: 72nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221232(US9303015, 6c | US9303015, 6b | US9303015, 6a)
Affinity DataIC50: 81nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221232(US9303015, 6c | US9303015, 6b | US9303015, 6a)
Affinity DataIC50: 85nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221236(US9303015, 10c | US9303015, 10b | US9303015, 10a)
Affinity DataIC50: 87nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221257(US9303015, 31c | US9303015, 31b | US9303015, 31a)
Affinity DataIC50: 88nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221262(US9303015, 36)
Affinity DataIC50: 89nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221236(US9303015, 10c | US9303015, 10b | US9303015, 10a)
Affinity DataIC50: 92nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221253(US9303015, 27c | US9303015, 27b | US9303015, 27a)
Affinity DataIC50: 95nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231227(US9346782, 7b | US9346782, 7c | US9346782, 7a)
Affinity DataIC50: 98nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221231(US9303015, 5c | US9303015, 5b | US9303015, 5a)
Affinity DataIC50: 100nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221261(US9303015, 35)
Affinity DataIC50: 100nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221246(US9303015, 20)
Affinity DataIC50: 110nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221254(US9303015, 28)
Affinity DataIC50: 110nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231231(US9346782, 11b | US9346782, 11c | US9346782, 11a)
Affinity DataIC50: 110nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221229(US9303015, 3c | US9303015, 3b | US9303015, 3a)
Affinity DataIC50: 120nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221258(US9303015, 32c | US9303015, 32b | US9303015, 32a)
Affinity DataIC50: 120nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221256(US9303015, 30c | US9303015, 30b | US9303015, 30a)
Affinity DataIC50: 140nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221243(US9303015, 17)
Affinity DataIC50: 150nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231221(US9346782, 1)
Affinity DataIC50: 150nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221229(US9303015, 3c | US9303015, 3b | US9303015, 3a)
Affinity DataIC50: 160nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221265(US9303015, 39)
Affinity DataIC50: 170nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231229(US9346782, 9b | US9346782, 9c | US9346782, 9a)
Affinity DataIC50: 180nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221257(US9303015, 31c | US9303015, 31b | US9303015, 31a)
Affinity DataIC50: 190nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231233(US9346782, 13c | US9346782, 13b | US9346782, 13a)
Affinity DataIC50: 200nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221253(US9303015, 27c | US9303015, 27b | US9303015, 27a)
Affinity DataIC50: 210nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231231(US9346782, 11b | US9346782, 11c | US9346782, 11a)
Affinity DataIC50: 210nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231234(US9346782, 14b | US9346782, 14c | US9346782, 14a)
Affinity DataIC50: 210nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221235(US9303015, 9c | US9303015, 9b | US9303015, 9a)
Affinity DataIC50: 220nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231227(US9346782, 7b | US9346782, 7c | US9346782, 7a)
Affinity DataIC50: 230nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221251(US9303015, 25c | US9303015, 25b | US9303015, 25a)
Affinity DataIC50: 250nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221260(US9303015, 34)
Affinity DataIC50: 250nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231230(US9346782, 10b | US9346782, 10c | US9346782, 10a)
Affinity DataIC50: 250nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221228(US9303015, 2c | US9303015, 2b | US9303015, 2a)
Affinity DataIC50: 260nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Artificial Sequence)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM231230(US9346782, 10b | US9346782, 10c | US9346782, 10a)
Affinity DataIC50: 260nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/5/2017
Entry Details
Go to US Patent

TargetNuclear receptor ROR-gamma [258-518,Y502F](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM221232(US9303015, 6c | US9303015, 6b | US9303015, 6a)
Affinity DataIC50: 270nMAssay Description:The reporter assay was performed by transiently transfecting HEK293T cells with 5 μg of pBIND-RORγt LBD or pBIND-RORγt LBD-AF2 and 5 &...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/10/2017
Entry Details
Go to US Patent

Displayed 1 to 50 (of 113 total ) | Next | Last >>
Jump to: